|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | | New England Journal of Medicine0，，： | 2 |
| 2 | Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 3 | Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy 显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 4 | Glycemic durabihty of rosiglitazone, mefformin, or glyburide monotherapy 显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 5 | Glycemic durability of rosiglitazone, mefformin, or glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，： | 1 |
| 6 | Glycenic durability of rosiglitazone, metformin, or glyburide monotherapy 显示文摘 | Kahn SE Haffner SM Heise MA | 2007 | N Engl J Med2007，355，： | 1 |
| 7 | Glycemic durability of rosiglitazone, mefforminor glyburide monotherapy显示文摘 | Kllhn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 8 | Glycemic durability of rosiglitazone, metformin or glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | Engl Med2006，355，23： | 1 |
| 9 | Glycemic durability of rosiglitazone,metformin,or Glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 10 | Glycemic durability of rosiglitazone, meffomin, or glyburide monotherapy 显示文摘 | KAHN SE HAFFNER SM HEISE MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 11 | Molecular cloning and characterization of a lysophosphatidic acid receptor,edg-7,expressed in prostate显示文摘 | Im DS Heise CE Harding MA | 2000 | Mol Pharmacol2000，57，： | 1 |
| 12 | Glycemic durability of rosiglitazone, metformin, or glyburide monotberapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，： | 1 |
| 13 | Glycemic durability of rosiglitazone,metformin,or glyberide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 14 | Rosiglitazone medidiated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patients 显示文摘 | Weston WM Heise MA Porter LE | 2001 | Diabetes2001，50，： | 1 |
| 15 | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 16 | Glycemic durability of rosiglitazone,mefformin,or glyburide monotherapy显示文摘 | Kabn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 17 | Glycemic durability of ros- iglitazone, metformin, or glyburide monotherapy 显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，： | 1 |
| 18 | Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy显示文摘 | Kahn SE Haffner SM Heise MA | 2006 | N Engl J Med2006，355，23： | 1 |
| 19 | Rosiglitazone medidiated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patients显示文摘 | Weston WM Heise MA Porter LE | 2001 | Diabetes2001，50，： | 1 |
| 20 | Rosiglitazone-mediated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patients显示文摘 | Weston WM Heise MA Porter LE | 2001 | Diabetes2001，50，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员